These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 33472857)

  • 1. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
    Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
    Liang B; Hu X; Ding Y; Liu M
    J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update.
    Sun D; Altalbawy FMA; Yumashev A; Hjazi A; Menon SV; Kaur M; Deorari M; Abdulwahid AS; Shakir MN; Gabal BC
    Cell Biochem Biophys; 2024 Sep; 82(3):1709-1720. PubMed ID: 38907940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
    Morrissey SM; Yan J
    Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application.
    Liu J; Qin J; Liang L; Zhang X; Gao J; Hao Y; Zhao P
    Eur J Pharmacol; 2024 Sep; 979():176831. PubMed ID: 39047964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
    Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
    Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer.
    Wu Y; Fu H; Hao J; Yang Z; Qiao X; Li Y; Zhao R; Lin T; Wang Y; Wang M
    Front Immunol; 2024; 15():1342728. PubMed ID: 38562933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
    Hudson K; Cross N; Jordan-Mahy N; Leyland R
    Front Immunol; 2020; 11():568931. PubMed ID: 33193345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.
    Wang G; Xie L; Li B; Sang W; Yan J; Li J; Tian H; Li W; Zhang Z; Tian Y; Dai Y
    Nat Commun; 2021 Sep; 12(1):5733. PubMed ID: 34593794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
    Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
    Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
    Poggio M; Hu T; Pai CC; Chu B; Belair CD; Chang A; Montabana E; Lang UE; Fu Q; Fong L; Blelloch R
    Cell; 2019 Apr; 177(2):414-427.e13. PubMed ID: 30951669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer cells synergistically defend against CD8
    Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
    Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
    Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 53.